181 related articles for article (PubMed ID: 34452831)
1. PRAME immunohistochemistry is useful in the diagnosis of oral malignant melanoma.
Hovander D; Allen J; Oda D; Moshiri AS
Oral Oncol; 2022 Jan; 124():105500. PubMed ID: 34452831
[TBL] [Abstract][Full Text] [Related]
2. PRAME immunohistochemistry is useful in differentiating oral melanomas from nevi and melanotic macules.
Schmitt TA; Lee JC; Martinka M; Ko KYC
J Cutan Pathol; 2023 Mar; 50(3):275-278. PubMed ID: 36398487
[TBL] [Abstract][Full Text] [Related]
3. PRAME Expression in Mucosal Melanoma of the Head and Neck Region.
Ricci C; Altavilla MV; Corti B; Pasquini E; Presutti L; Baietti AM; Amorosa L; Balbi T; Baldovini C; Ambrosi F; Grillini M; D'Errico A; Fiorentino M; Foschini MP
Am J Surg Pathol; 2023 May; 47(5):599-610. PubMed ID: 36912431
[TBL] [Abstract][Full Text] [Related]
4. PRAME expression in melanocytic proliferations with intermediate histopathologic or spitzoid features.
Raghavan SS; Wang JY; Kwok S; Rieger KE; Novoa RA; Brown RA
J Cutan Pathol; 2020 Dec; 47(12):1123-1131. PubMed ID: 32700786
[TBL] [Abstract][Full Text] [Related]
5. The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors.
Alomari AK; Tharp AW; Umphress B; Kowal RP
J Cutan Pathol; 2021 Sep; 48(9):1115-1123. PubMed ID: 33660310
[TBL] [Abstract][Full Text] [Related]
6. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
Lohman ME; Steen AJ; Grekin RC; North JP
J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
[TBL] [Abstract][Full Text] [Related]
7. PReferentially Expressed Antigen in MElanoma (PRAME): preliminary communication on a translational tool able to early detect Oral Malignant Melanoma (OMM).
Cascardi E; Cazzato G; Ingravallo G; Dellino M; Lupo C; Casatta N; Ballini A; Pacifici A; Marenzi G; Sammartino G; Maiorano E; Tatullo M
J Cancer; 2023; 14(4):628-633. PubMed ID: 37057287
[TBL] [Abstract][Full Text] [Related]
8. PRAME expression in 137 primary cutaneous melanomas and comparison with 38 related metastases.
Lo Bello G; Pini GM; Giagnacovo M; Patriarca C
Pathol Res Pract; 2023 Nov; 251():154915. PubMed ID: 37913637
[TBL] [Abstract][Full Text] [Related]
9. Correlation of FISH and PRAME Immunohistochemistry in Ambiguous Superficial Cutaneous Melanocytic Proliferations.
Harvey NT; Peverall J; Acott N; Mesbah Ardakani N; Leecy TN; Iacobelli J; McCallum D; Van Vliet C; Wood BA
Am J Dermatopathol; 2021 Dec; 43(12):913-920. PubMed ID: 33899766
[TBL] [Abstract][Full Text] [Related]
10. A Comparison of Preferentially Expressed Antigen in Melanoma Immunohistochemistry and Diagnostic Gene Expression-Profiling Assay in Challenging Melanocytic Proliferations.
Casillas AC; Muhlbauer A; Barragan VA; Jefferson I; Speiser JJ
Am J Dermatopathol; 2024 Mar; 46(3):137-146. PubMed ID: 38354382
[TBL] [Abstract][Full Text] [Related]
11. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review.
Turner N; Ko CJ; McNiff JM; Galan A
Am J Dermatopathol; 2024 Jan; 46(1):21-30. PubMed ID: 37982498
[TBL] [Abstract][Full Text] [Related]
12. Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation.
Fattori A; de la Fouchardière A; Cribier B; Mitcov M
Hum Pathol; 2022 Mar; 121():19-28. PubMed ID: 34990622
[TBL] [Abstract][Full Text] [Related]
13. [Application of immunohistochemical staining of PRAME in differential diagnosis between melanoma and melanocytic nevus].
Du J; Yu WJ; Guo RP; Su J
Zhonghua Bing Li Xue Za Zhi; 2022 Jul; 51(7):621-626. PubMed ID: 35785832
[No Abstract] [Full Text] [Related]
14. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
15. PRAME expression in melanocytic lesions of the nail.
Parra O; Linos K; Li Z; Yan S
J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
[TBL] [Abstract][Full Text] [Related]
16. PRAME Expression Correlates With Genomic Aberration and Malignant Diagnosis of Spitzoid Melanocytic Neoplasms.
Gerami P; Benton S; Zhao J; Zhang B; Lampley N; Roth A; Boutko A; Olivares S; Busam KJ
Am J Dermatopathol; 2022 Aug; 44(8):575-580. PubMed ID: 35503885
[TBL] [Abstract][Full Text] [Related]
17. Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions.
Olds H; Utz S; Abrams J; Terrano D; Mehregan D
J Cutan Pathol; 2022 Jun; 49(6):510-514. PubMed ID: 35146798
[TBL] [Abstract][Full Text] [Related]
18. PRAME Immunohistochemistry as an Ancillary Test for the Assessment of Melanocytic Lesions.
Lezcano C; Jungbluth AA; Busam KJ
Surg Pathol Clin; 2021 Jun; 14(2):165-175. PubMed ID: 34023098
[TBL] [Abstract][Full Text] [Related]
19. FLI-1/Melan-A dual stain is an alternative to PRAME in differentiating metastatic melanoma from nodal nevus: A monocentric retrospective study.
Zengin HB; Yildiz B; Pukhalskaya T; Smoller BR
J Cutan Pathol; 2023 Mar; 50(3):247-258. PubMed ID: 36454046
[TBL] [Abstract][Full Text] [Related]
20. PRAME immunohistochemistry is useful in the evaluation of conjunctival melanomas, nevi, and primary acquired melanosis.
LeBlanc RE; Miller DM; Zegans ME
J Cutan Pathol; 2021 Dec; 48(12):1442-1448. PubMed ID: 34089198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
